Latest Lapatinib Stories

Peregrine Pharmaceuticals has announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The new trial is the second Phase II study evaluating bavituximab in advanced breast cancer patients, and Peregrine also is conducting a third Phase II combination therapy trial of bavituximab in non-small cell lung cancer patients. The primary objective...

The UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK. This recommendation suggests that NICE is likely to look unfavorably on a number of other targeted therapies in development, severely limiting future growth of the targeted cancer therapies market in the UK. In its preliminary guidance report on a number of new targeted cancer therapies, the UK's...

GlaxoSmithKline plans to renegotiate with the UK's Department of Health as part of its attempt to reverse the National Health Service's decision regarding the company's cancer drug Tyverb, reported the Financial Times. According to the news source, GlaxoSmithKline (GSK) is proposing a new 'price-volume' deal to address the concerns of the National Institute for Health and Clinical Excellence (NICE), the government's medicines advisory body, which considers Tyverb as too costly when compared...

Ariad Pharmaceuticals has initiated a Phase II clinical trial to examine the efficacy and safety of oral deforolimus, its investigational mTOR inhibitor, in patients with advanced breast cancer. In collaboration with Merck & Co, deforolimus is currently being evaluated in multiple clinical trials, both alone and in combination with other therapies, for the treatment of patients with several different cancer types. Under terms of the agreement, Ariad will receive a $15 million milestone...

The medical advisory panel to the UK National Health Service has recommended that GlaxoSmithKline's Tyverb should not be used on the NHS to treat advanced metastatic breast cancer on the grounds that it is not effective enough to justify its cost. This decision represents not only a blow to GSK but also casts doubt on how many other new cancer therapies will be available in the UK. The UK panel ruled that, based on data showing that the median survival time for women who received Tyverb...

The National Institute of Health and Clinical Excellence has advised against the use of GlaxoSmithKline's oral cancer drug Tyverb in the UK's National Health Service, reported the Financial Times. According to the Financial Times, The National Institute of Health and Clinical Excellence (NICE) has issued a provisional recommendation that Tyverb for advanced breast cancer failed to meet its threshold for clinical and cost effectiveness. GSK tried to negotiate a 'risk-sharing' arrangement...

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the results of a Phase Ib clinical trial designed to evaluate ispinesib in combination with capecitabine, an oral chemotherapy agent commonly used in the treatment of breast cancer. Ispinesib is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib, along with another KSP inhibitor, SB-743921 are chemically-distinct drug candidates that have arisen from a...

By Claire Harrison Dr Seamus McAleer has been involved in trials of a new drug called Lapatinib at Belfast City Hospital which has offered women suffering a type of advanced breast cancer hope by slowing the disease. Around 1,000 women are diagnosed with breast cancer in Northern Ireland every year, with a quarter suffering the aggressive, fast- growing ErbB2-positive kind of the disease. For many women with this form of the disease who initially respond to treatment with Herceptin and...

A CANCER drug that Jane Tomlinson's husband said should be made widely available has been launched in the UK. Lapatinib can prolong the lives of women suffering a type of advanced breast cancer by stopping the disease from growing. Around a quarter of women with breast cancer are diagnosed with the HER2-positive form of the disease. The drug is for women whose advanced disease has stopped responding to Herceptin. Also known as Tyverb, the drug has received its European licence, making...

KIM Robson pounded the streets of Leeds in Jane Tomlinson's Run for All last year and will line up with thousands of others against for the event next week. She began running to keep fit only two years ago but soon after taking part in a fun run for cancer research, her world was turned upside down when she found a lump in her breast. Her GP in Ilkley referred her for tests which confirmed she had cancer. She underwent chemotherapy and then had major surgery on a fast- growing...